Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

1 Jul 2002

Abstract excerpt

Therapeutic use of the recently FDA-approved drug STI571 has been successful in the treatment of Philadelphia chromosome-positive leukemias. STI571 is a small molecule inhibitor with activity against BCR-ABL, the deregulated tyrosine kinase responsible for initiation and maintenance of the disease in the chronic phase of chronic myeloid leukemia (CML). Clinical trials demonstrated the ability of STI571 to induce...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12042704
DOI: 10.1097/00062752-200207000-00007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemiaPMID 12042704Read ↗

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.Semantic proximity Read ↗

[STI571: a summary of targeted therapy].Semantic proximity Read ↗

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cellsSemantic proximity Read ↗

Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia.Semantic proximity Read ↗

[Novel inhibitors of Bcr-Abl].Semantic proximity Read ↗

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Semantic proximity Read ↗

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.Semantic proximity Read ↗

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.Semantic proximity Read ↗

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336Semantic proximity Read ↗

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationSemantic proximity Read ↗

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.Semantic proximity Read ↗

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.